Status:
RECRUITING
Prospective Study on the Efficacy and Safety of Bronchoalveolar Lavage Combined With Pathogen Metagenomic Sequencing Technology in the Diagnosis of Immune Checkpoint Inhibitor Associated Pneumonia
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Immune Checkpoint Inhibitor Associated Pneumonia
Eligibility:
All Genders
18-75 years
Brief Summary
Immune checkpoint inhibitor associated pneumonia (CIP) is a common immune related adverse reaction, accounting for 35% of all deaths. However, due to the lack of typical clinical symptoms and imaging ...
Eligibility Criteria
Inclusion
- Voluntarily sign an informed consent form;
- Age range from 18 to 75 years old, regardless of gender;
- Immunosuppressive host;
- Symptoms, signs, or imaging signs of pneumonia are visible, and empirical anti infection treatment is ineffective.
Exclusion
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT06192303
Start Date
January 1 2023
End Date
January 1 2026
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China